期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Prognostic Analysis and an Appropriate Antiplatelet Strategy for Patients With Percutaneous Coronary Intervention and High Bleeding Risk:Rationale and Protocol for a MultiCenter Cohort Study
1
作者 Junyan Zhang Zhongxiu Chen +6 位作者 Hua Wang Mian Wang Chen Li Sen He Yong Peng Jiafu Wei Yong He 《Cardiology Discovery》 2024年第3期213-220,共8页
Percutaneous coronary intervention(PCI)is an important treatment strategy for patients with coronary artery disease.However,bleeding after PCI significantly increases the mortality risk.The search for prognostic predi... Percutaneous coronary intervention(PCI)is an important treatment strategy for patients with coronary artery disease.However,bleeding after PCI significantly increases the mortality risk.The search for prognostic predictors and optimal antiplatelet therapy for patients with high bleeding risk(HBR)after PCI has been a much researched upon topic in current cardiovascular research.However,there is no widely accepted prognostic model or recommended antiplatelet therapy for patients with PCI-HBR.In this trial,based on prospective multi-center database building,we will analyze the adverse prognostic predictors for patients with PCI-HBR,observe the types of antiplatelet drugs and duration of dual antiplatelet therapy in PCI-HBR patients,and compare the safety and feasibility of different antiplatelet regimens and treatment courses.The prognostic analysis and an appropriate antiplatelet strategy for patients with PCI and high bleeding risk(PPP-PCI)trial will help analyze bleeding risk factors in PCI-HBR patients and explore the appropriate antiplatelet treatment options.This study is registered with ClinicalTrials.gov(NCT05369442).The Research Ethics Committee of West China Hospital authorized this study(2022 Review#269).The trial results will be published in peer-reviewed journals and at conferences. 展开更多
关键词 Percutaneous coronary intervention high bleeding risk Dual antiplatelet therapy
原文传递
Drug-coated balloon-only strategy for percutaneous coronary intervention of de novo left main coronary artery disease: the importance of proper lesion preparation
2
作者 Sanna Uskela Antti Eranti +1 位作者 Jussi MKärkkäinen Tuomas TRissanen 《Frontiers of Medicine》 SCIE CSCD 2023年第1期75-84,共10页
This retrospective single-center registry study included all consecutive patients who underwent percutaneous coronary intervention (PCI) for a de novo left main coronary artery lesion using drug coated-balloon (DCB)-o... This retrospective single-center registry study included all consecutive patients who underwent percutaneous coronary intervention (PCI) for a de novo left main coronary artery lesion using drug coated-balloon (DCB)-only strategy between August 2011 and December 2018. To best of our knowledge, no previous studies of DCB-only strategy of treating de novo left main coronary artery disease, exist. The primary endpoint was major adverse cardiovascular events (MACEs) including cardiac death, non-fatal myocardial infarction, and target lesion revascularization (TLR). The cohort was divided into two groups depending on weather the lesion preparation was done according to the international consensus group guidelines. Sixty-six patients (mean age 75±8.6, 72% male), 52% of whom had acute coronary syndrome, underwent left main PCI with the DCB-only strategy. No procedural mortality and no acute closures of the treated left main occurred. At 12 months, MACE and TLR occurred in 24% and 6% of the whole cohort, respectively. If the lesion preparation was done according to the guidelines, the MACE and TLR rates were 21.2% and 1.9%. Left main PCI with the DCB only-strategy is safe leading to acceptable MACE and low TLR rates at one year, if the lesion preparation is done according to the guidelines. 展开更多
关键词 drug-coated balloon left main high bleeding risk predilatation calcifield lesion percutaneous coronary intervention
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部